Thursday 7 May, 2026
Introduction: Niclosamide has demonstrated potent broad-spectrum antiviral activity against respiratory viruses, including SARS-CoV-2 and influenza [1, 2], but exhibits poor…
Read moreAbstracts
Population pharmacokinetic analysis of etoposide and model-based dosing evaluation in pediatric oncology
Thursday 7 May, 2026
Introduction Etoposide is an antineoplastic podophyllotoxin derivative that inhibits topoisomerase II, resulting in irreversible DNA strand breaks and cell apoptosis…
Read moreModeling expanded disability status scale trajectories and their association with serum neurofilament light chan in alemtuzumab-treatment relapsing remitting multiple sclerosis patients
Thursday 7 May, 2026
Introduction: Relapsing‑Remitting Multiple Sclerosis (RRMS) is an autoimmune disease characterized by demyelinating lesions and progressive neurological impairment(1). While reducing relapse…
Read moreA novel workflow integrating PET microdosing data and therapeutic-dose pharmacokinetics across species to inform first-in-human dose selection
Thursday 7 May, 2026
Introduction:Â First-in-human (FiH) studies require a range of doses extrapolated from pharmacokinetic (PK) animal studies combined with safety assessments. Subtherapeutic doses…
Read moreInterpretable Deep Learning Survival Analysis of Alzheimer’s Disease Using Genetic Variants Associated with Metabolic Disorders
Thursday 7 May, 2026
Objectives: Alzheimer’s disease (AD) is a progressive and multifactorial neurodegenerative disorder resulting from a highly complex interplay of genetic and…
Read moreOPTIMISING POSACONAZOLE DOSING IN CHILDREN THROUGH POPULATION PHARMACOKINETIC MODELLING AND SIMULATION
Thursday 7 May, 2026
Introduction: Invasive aspergillosis remains a major cause of morbidity and mortality in paediatric patients with immunodeficiencies and haematological cancers. Posaconazole…
Read more(Val)ganciclovir against cytomegalovirus: Are we currently dosing too low?
Thursday 7 May, 2026
Objectives Cytomegalovirus (CMV) is a human herpesvirus that causes significant mortality and morbidity in immunocompromised patients (1). The first-line drug,…
Read moreUsing Generative AI Variational Autoencoders with Neural Ordinary Differential Equations to Improve Nonlinear Mixed-Effects Pharmacometric Modeling
Thursday 7 May, 2026
Objectives Pharmacometrics (PMX) modeling is essential for optimizing drug therapy and drug development. Nonlinear Mixed-Effects (NLME) modeling is used to…
Read moreModel-based assessment of the prothrombin time test during transition from rivaroxaban to warfarin
Thursday 7 May, 2026
Objectives For patients receiving long-term anticoagulant therapy, various clinical situations may arise in which it is necessary to transition from…
Read moreUsing copulas to quantify patient representation and model suitability in model-informed precision dosing
Thursday 7 May, 2026
Objectives: Model-Informed Precision Dosing (MIPD) leverages population pharmacokinetic (PK) models to predict optimal dose adjustments that incorporate patient covariates to…
Read more